Race is a social construct, but representation matters in genetic studies — and on that front, we have a long way to go. By Tala Berro, MS, CGC
Genetic testing in healthy individuals
In this study led by UCSF researchers, exome sequencing was found to produce more false positives and false negatives for inherited metabolic disorders than the standard blood testing conducted in newborns. G2P’s Dr. Robert Green, co-leader of the BabySeq Project, speaks to the possibility “that the most comprehensive screening for newborns will be some combination … Continued
Dr. Robert Green is the director of the Preventive Genomics Clinic at Brigham and Women’s Hospital in Boston. He believes that DNA testing combined with proper counseling and medical follow-up would be a critical element of a healthcare system that can prevent illness.
An exclusive Clinical OMICs conversation with the director of Genomes2People, Robert Green, M.D., MPH
Greg and Robert explode some of the persistent myths around genetic testing and dive in to the future of genetic testing amongst healthy populations
Through national research efforts like the All of Us Research Program, Brigham investigators and their collaborators are making genomic research more meaningful, equitable and impactful for all patients at the Brigham and around the world.
Whole genome tests can help identify the cause of a baby’s mysterious illness. But ethicists say it’s still too soon to use them for all infants.
“Our research is finding that genetics is about to take its rightful place in medical care for the world.” said Dr. Robert Green, a professor of genetics at Harvard Medical School.
Companies claim they can now easily calculate your biological age. Should you take them up on it?
A new epigenetic test that tracks molecular aging claims to show you how to stay biologically young. However, Robert Green says “epigenetic marks in apparently healthy people can tell them meaningful things about their health status is an overreach.”
“It’s really exciting that to see companies move to preserve health, rather than just treating patients when they’re ill,” said Dr. Robert Green, a medical geneticist at Harvard Medical School and a co-founder of a genetics company called Genome Medical.
We now have the ability to screen for thousands of genetic diseases in newborns. That may not always be the healthy thing to do.
BGI is racing toward a world where your DNA informs your medical decisions—and maybe some of your personal ones. Bloomberg asks Dr. Robert Green on his thoughts regarding the medical advances in genomics in China and how they compare to those in the US.
The ultimate aim of our Genomes2People Research Program is to contribute to the transformation of medicine from reactive to proactive, from treatment-oriented to preventive. We are trying to help build the evidence base that will justify societal decision to make these technologies and services accessible to anyone who wants them, regardless of means, education or … Continued
Genetic scans provide lots of information, but only a fraction is returned to patients. Dr. Robert Green states “It’s their body and their DNA. We have a responsibility to scientific truth and clear communication.”
“Preventive genomics is not yet recommended as standard of care,” Robert Green, director of the Preventive Genomics Clinic, said in a statement. “But for over two decades, our NIH-funded, randomized trials in translational genomics have generated consistent evidence that there are more potential medical benefits and fewer risks than previously considered. It is time for … Continued
Brigham and Women’s Hospital has launched the Preventive Genomics Clinic, a facility designed to provide comprehensive DNA sequencing, interpretation and reporting of disease-associated genes.
Dr. Jason Vassey was announced as one of six recipients for the Genomic Innovator supporting early career investigators researching genome biology, genomic medicine, technology development and societal implications of genomic advances.
Researchers led by Robert Green at Brigham and Women’s Hospital looked at whether consumers getting direct-to-consumer genetic testing were using PGx tests to change treatment decisions. Although this study relied on self-reported data from participants, it suggests that less than 1 percent could have made unsupervised medication changes based on their genetic test results.
Brigham and Women’s Hospital on Friday unveiled a new Preventive Genomics Clinic that will offer a menu of options for a genetic workup, with price tags ranging from $250 to $2,950, depending on how many genes are analyzed; it’s the first program of its kind that will offer the sequencing to children in addition to adults.
The preventive genomics clinic is offering what’s arguably the opposite of modestly priced, do-it-yourself tests: It’s a full-service genomics clinic for patients who want the elite care of an academic medical center and will pay for it out of pocket.
Nation’s first academic clinic to offer comprehensive DNA sequencing and genetic risk assessment to healthy adults and children
“I would have never known that I was at risk if i hadn’t donated to the Biobank,” said Kristine Trudeau who knowingly enrolled in the Partners HealthCare Biobank because she wanted to help advance medicine and potentially save lives. She did not expect that it would save her own.
The first major randomized clinical trial on the effect of disclosing genetic information found that people who decided to learn about their genetic risk of developing Alzheimer’s disease did not experience large, negative psychological impacts.
More and more people want to explore their own medical data, and a DTC genetic test is one way to begin to understand some aspects of your future health.
At a new clinic in Boston, genetic counselor Carrie Blout helps healthy patients get their DNA tested for predispositions to more than 2500 diseases. Bloomberg’s Aki Ito goes through the testing herself, trialing a controversial technology at the forefront of modern medicine.
Dr. Robert Green and Kreg Klugman explore the pros and cons of knowing one’s risk for developing Alzheimer’s.
Babies are tested for a number of conditions soon after birth, but varied approaches to screening worldwide highlight how fragmented the medical profession remains over this vital process.
MIT scientists used a novel tool to try to edit out a genetic risk for Alzheimer’s disease, they report in the journal Science. Dr. Robert Green gives his opinion on the new technology.